Mark Mcdade - Net Worth and Insider Trading
Mark Mcdade Net Worth
The estimated net worth of Mark Mcdade is at least $12 Million dollars as of 2024-05-11. Mark Mcdade is the Director of Tourmaline Bio Inc and owns about 742,209 shares of Tourmaline Bio Inc (TRML) stock worth over $11 Million. Mark Mcdade is the Director of Aimmune Therapeutics Inc and owns about 16,660 shares of Aimmune Therapeutics Inc (AIMT) stock worth over $574,603. Mark Mcdade is also the Director of NetSuite Inc and owns about 3,156 shares of NetSuite Inc (N) stock worth over $285,113. Besides these, Mark Mcdade also holds PDL BioPharma Inc (PDLI) . Details can be seen in Mark Mcdade's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Mark Mcdade has not made any transactions after 2024-01-29 and currently still holds the listed stock(s).
Transaction Summary of Mark Mcdade
Mark Mcdade Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Mark Mcdade owns 8 companies in total, including Aimmune Therapeutics Inc (AIMT) , Dermira Inc (DERM) , and Five Prime Therapeutics Inc (FPRX) among others .
Click here to see the complete history of Mark Mcdade’s form 4 insider trades.
Insider Ownership Summary of Mark Mcdade
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| AIMT | Aimmune Therapeutics Inc | 2020-10-10 | director |
| DERM | Dermira Inc | 2020-02-20 | director |
| FPRX | Five Prime Therapeutics Inc | 2018-05-10 | director |
 | | 2005-04-05 | director |
| | 2007-07-20 | director & CEO |
| | 2021-07-28 | 10 percent owner |
| | 2023-01-27 | 10 percent owner |
| | 2021-05-06 | director |
Mark Mcdade Latest Holdings Summary
Mark Mcdade currently owns a total of 4 stocks. Among these stocks, Mark Mcdade owns 742,209 shares of Tourmaline Bio Inc (TRML) as of January 29, 2024, with a value of $11 Million and a weighting of 91.57%. Mark Mcdade owns 16,660 shares of Aimmune Therapeutics Inc (AIMT) as of August 11, 2015, with a value of $574,603 and a weighting of 4.89%. Mark Mcdade also owns 3,156 shares of NetSuite Inc (N) as of July 17, 2015, with a value of $285,113 and a weighting of 2.43%. The other 1 stocks PDL BioPharma Inc (PDLI) have a combined weighting of 1.12% among all his current holdings.
Latest Holdings of Mark Mcdade
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| TRML | Tourmaline Bio Inc | 2024-01-29 | 742,209 | 14.50 | 10,762,031 |
| AIMT | Aimmune Therapeutics Inc | 2015-08-11 | 16,660 | 34.49 | 574,603 |
| N | NetSuite Inc | 2015-07-17 | 3,156 | 90.34 | 285,113 |
| PDLI | PDL BioPharma Inc | 2007-01-17 | 53,137 | 2.47 | 131,248 |
Holding Weightings of Mark Mcdade
Mark Mcdade Form 4 Trading Tracker
According to the SEC Form 4 filings, Mark Mcdade has made a total of 1 transactions in Tourmaline Bio Inc (TRML) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Tourmaline Bio Inc is the acquisition of 100,000 shares on January 29, 2024, which cost Mark Mcdade around $3 Million.
According to the SEC Form 4 filings, Mark Mcdade has made a total of 0 transactions in Aimmune Therapeutics Inc (AIMT) over the past 5 years. The most-recent trade in Aimmune Therapeutics Inc is the acquisition of 16,660 shares on August 11, 2015, which cost Mark Mcdade around $266,560.
According to the SEC Form 4 filings, Mark Mcdade has made a total of 0 transactions in NetSuite Inc (N) over the past 5 years. The most-recent trade in NetSuite Inc is the acquisition of 422 shares on July 17, 2015, which cost Mark Mcdade around $9,495.
More details on Mark Mcdade's insider transactions can be found in the Insider Trading History of Mark Mcdade table.Insider Trading History of Mark Mcdade
- 1
Mark Mcdade Trading Performance
GuruFocus tracks the stock performance after each of Mark Mcdade's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Mark Mcdade is -21.19%. GuruFocus also compares Mark Mcdade's trading performance to market benchmark return within the same time period. The performance of stocks bought by Mark Mcdade within 3 months outperforms 1 times out of 4 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Mark Mcdade's insider trading performs compared to the benchmark.
Performance of Mark Mcdade
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | 4.01 | | | | | |
| Relative Return to S&P 500(%) | 4.76 | | | | | |
Mark Mcdade Ownership Network
Mark Mcdade Owned Company Details
What does Aimmune Therapeutics Inc do?
Who are the key executives at Aimmune Therapeutics Inc?
Mark Mcdade is the director of Aimmune Therapeutics Inc. Other key executives at Aimmune Therapeutics Inc include 10 percent owner Societe Des Produits Nestle S.a. , Chief Financial Officer Eric Bjerkholt , and Chief Medical Officer Adelman Daniel C Md .
Aimmune Therapeutics Inc (AIMT) Insider Trades Summary
In summary, during the past 3 months, insiders sold 0 shares of Aimmune Therapeutics Inc (AIMT) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Aimmune Therapeutics Inc (AIMT) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.
Aimmune Therapeutics Inc (AIMT)'s detailed insider trading history can be found in Insider Trading Tracker table.
Aimmune Therapeutics Inc Insider Transactions
Mark Mcdade Mailing Address
Above is the net worth, insider trading, and ownership report for Mark Mcdade. You might contact Mark Mcdade via mailing address: C/o Protine Design Lab, 7442 North Marcer Way, Mercer Island Wa 98040.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
